^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CTLA4 antagonist

    Related drugs:
    3d
    QLMA-IIT-CC-001: Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC (clinicaltrials.gov)
    P2, N=30, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Qibeian (iparomlimab/tuvonralimab)
    6d
    KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer (clinicaltrials.gov)
    P1, N=54, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Nov 2028 --> Jul 2029 | Trial primary completion date: Nov 2028 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181) • Hiltonol (poly-ICLC)
    10d
    CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Chinese PLA General Hospital | Recruiting --> Active, not recruiting | N=15 --> 9 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment closed • Enrollment change • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12
    |
    Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC
    16d
    Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    cisplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    21d
    A Study of Botensilimab and Balstilimab for Colorectal Cancer (clinicaltrials.gov)
    P2, N=284, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial • Circulating tumor DNA
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    24d
    NCI-2022-09458: FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    POLE (DNA Polymerase Epsilon)
    |
    POLE mutation
    |
    Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • fluorouracil topical
    29d
    Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, City of Hope Medical Center | Trial primary completion date: Oct 2025 --> May 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Stivarga (regorafenib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    2ms
    Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors (clinicaltrials.gov)
    P2, N=92, Terminated, Prisma Health-Upstate | N=150 --> 92 | Trial completion date: Dec 2028 --> Sep 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Sep 2025; poor enrollment likely due to expanded availability of immunotherapy for patients
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • IO biomarker
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    3ms
    Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer (clinicaltrials.gov)
    P1/2, N=64, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    carboplatin • Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)
    3ms
    BATTMAN: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma (clinicaltrials.gov)
    P3, N=834, Not yet recruiting, Canadian Cancer Trials Group
    New P3 trial
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    4ms
    Botensilimab, Balstilimab, and SBRT in Colorectal Cancer (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Massachusetts General Hospital
    New P1 trial • MSI-H • pMMR
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    4ms
    NEST-1: Combination Immunotherapy in Colorectal Cancer (clinicaltrials.gov)
    P2, N=36, Suspended, Weill Medical College of Cornell University | Trial completion date: Dec 2025 --> Jun 2026 | Recruiting --> Suspended | Trial primary completion date: May 2025 --> Nov 2025
    Trial completion date • Trial suspension • Trial primary completion date
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)